• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

瑞伐沙班剂量调整采用血栓生成在严重先天性蛋白 C 缺乏和华法林诱导的皮肤坏死。

Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis.

机构信息

Division of Hematology/Oncology, Department of Pediatrics, and.

Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX.

出版信息

Blood Adv. 2018 Jan 23;2(2):142-145. doi: 10.1182/bloodadvances.2017012047.

DOI:10.1182/bloodadvances.2017012047
PMID:29365322
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5787863/
Abstract

Rivaroxaban was efficacious and safe in a child with protein C deficiency to prevent the recurrence of skin necrosis or venous thrombosis. The dosage of direct oral anticoagulants in children with thrombophilia is unclear; a thrombin generation assay may be useful to adjust it.

摘要

利伐沙班可有效且安全地用于预防蛋白 C 缺乏症儿童皮肤坏死或静脉血栓形成的复发。对于血栓形成倾向的儿童，直接口服抗凝剂的剂量尚不清楚；血栓生成试验可能有助于调整剂量。

相似文献

1
Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis.瑞伐沙班剂量调整采用血栓生成在严重先天性蛋白 C 缺乏和华法林诱导的皮肤坏死。
Blood Adv. 2018 Jan 23;2(2):142-145. doi: 10.1182/bloodadvances.2017012047.
2
Anticoagulation therapy for thromboembolism prevention: a case of warfarin-induced skin necrosis in the setting of protein C deficiency.预防血栓栓塞的抗凝治疗：蛋白C缺乏情况下华法林所致皮肤坏死1例。
BMJ Case Rep. 2017 May 12;2017:bcr-2016-218015. doi: 10.1136/bcr-2016-218015.
3
Priapism: an unusual manifestation of warfarin-induced skin necrosis with protein C deficiency.阴茎异常勃起：华法林诱导的皮肤坏死合并蛋白C缺乏的一种罕见表现。
J Assoc Physicians India. 2006 Dec;54:963-4.
4
Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban.利伐沙班治疗纯合子先天性蛋白S缺乏症患者的凝血酶生成及其他凝血参数
Int J Hematol. 2016 Feb;103(2):165-72. doi: 10.1007/s12185-015-1898-6. Epub 2015 Nov 19.
5
Warfarin-induced skin necrosis: a case report.
Clin Appl Thromb Hemost. 2006 Jan;12(1):101-4. doi: 10.1177/107602960601200117.
6
Warfarin-Induced Skin Necrosis in Patients With Low Protein C Levels.蛋白C水平低的患者中由华法林引起的皮肤坏死
Acta Med Iran. 2016 Aug;54(8):551-554.
7
Evidence that the protein C activation pathway amplifies the inhibition of thrombin generation by recombinant human thrombomodulin in plasma.有证据表明，蛋白C激活途径可增强重组人血栓调节蛋白对血浆中凝血酶生成的抑制作用。
Thromb Haemost. 1993 Sep 1;70(3):423-6.
8
Warfarin-induced benign acral cutaneous lesions in two cardiac patients with decreased protein C and S activity.两名蛋白C和S活性降低的心脏病患者出现华法林诱导的良性肢端皮肤病变。
Anadolu Kardiyol Derg. 2008 Aug 7;8(4):E22.
9
Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis.
Ann Intern Med. 1986 May;104(5):659-60. doi: 10.7326/0003-4819-104-5-659.
10
Severe skin necrosis following warfarin therapy in a patient with protein C deficiency.
J Intern Med. 1993 Mar;233(3):287-9. doi: 10.1111/j.1365-2796.1993.tb00989.x.

引用本文的文献

1
Addressing challenges in pediatric thrombosis: a comprehensive guideline development.应对儿童血栓形成的挑战：全面指南的制定
Front Pediatr. 2025 Jan 27;13:1519517. doi: 10.3389/fped.2025.1519517. eCollection 2025.
2
Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases.用于出血和血栓性疾病个性化治疗的凝血酶生成检测。
Front Cardiovasc Med. 2022 Nov 10;9:1033416. doi: 10.3389/fcvm.2022.1033416. eCollection 2022.
3
Inherited Thrombophilia in the Era of Direct Oral Anticoagulants.直接口服抗凝剂时代的遗传性血栓形成倾向。
Int J Mol Sci. 2022 Feb 5;23(3):1821. doi: 10.3390/ijms23031821.
4
A Case of Treatment With Dabigatran for Cerebral Venous Thrombosis Caused by Hereditary Protein C Deficiency.1例遗传性蛋白C缺乏所致脑静脉血栓形成的达比加群治疗病例
Cureus. 2021 Jun 6;13(6):e15473. doi: 10.7759/cureus.15473. eCollection 2021 Jun.
5
Successful treatment of warfarin-induced skin necrosis using oral rivaroxaban: A case report.口服利伐沙班成功治疗华法林诱导的皮肤坏死：一例报告。
World J Clin Cases. 2019 Dec 26;7(24):4285-4291. doi: 10.12998/wjcc.v7.i24.4285.

本文引用的文献

1
Anticoagulation therapy for thromboembolism prevention: a case of warfarin-induced skin necrosis in the setting of protein C deficiency.预防血栓栓塞的抗凝治疗：蛋白C缺乏情况下华法林所致皮肤坏死1例。
BMJ Case Rep. 2017 May 12;2017:bcr-2016-218015. doi: 10.1136/bcr-2016-218015.
2
Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?用于低分子量肝素的抗Xa测定能否用于评估利伐沙班的存在情况？
Transfus Apher Sci. 2016 Oct;55(2):212-215. doi: 10.1016/j.transci.2016.06.005. Epub 2016 Jun 27.
3
Hypercoagulability in adolescent girls on oral contraceptives-global coagulation profile and estrogen receptor polymorphisms.口服避孕药致青春期少女高凝状态：整体凝血谱及雌激素受体多态性。
Am J Hematol. 2015 Aug;90(8):725-31. doi: 10.1002/ajh.24064.
4
Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.非维生素K拮抗剂口服抗凝剂与传统抗凝剂的检测：止血检测的合理应用
Thromb J. 2014 Nov 4;12:24. doi: 10.1186/1477-9560-12-24. eCollection 2014.
5
Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method.使用Heptest-STAT凝血方法测定患者血浆中的非维生素K拮抗剂口服抗凝剂。
Ther Drug Monit. 2015 Jun;37(3):375-80. doi: 10.1097/FTD.0000000000000157.
6
Anticoagulant treatment with rivaroxaban in severe protein S deficiency.利伐沙班治疗严重蛋白 S 缺乏症的抗凝治疗。
Pediatrics. 2013 Nov;132(5):e1435-9. doi: 10.1542/peds.2013-1156. Epub 2013 Oct 21.
7
Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban.比较发色底物抗 Xa 测定和 PT 试验与 LC-MS/MS 在利伐沙班治疗患者的治疗监测中的应用。
Thromb Haemost. 2013 Oct;110(4):723-31. doi: 10.1160/TH13-04-0274. Epub 2013 Jul 11.
8
Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays.在常规临床实践中检测利伐沙班：何时、如何以及使用哪种检测方法。
Ann Med. 2013 Sep;45(5-6):423-9. doi: 10.3109/07853890.2013.801274. Epub 2013 Jun 7.
9
Dabigatran etexilate (Pradaxa®) for preventing warfarin-induced skin necrosis in a patient with severe protein C deficiency.
Thromb Haemost. 2012 Jun;107(6):1189-91. doi: 10.1160/TH11-11-0788. Epub 2012 Mar 8.
10
Assays for measuring rivaroxaban: their suitability and limitations.用于检测利伐沙班的检测方法：适用性和局限性。
Ther Drug Monit. 2010 Dec;32(6):673-9. doi: 10.1097/FTD.0b013e3181f2f264.